Peter Wrighton Smith News Today

AUSTIN, Texas and OXFORD, U.K., Dec. 7, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a developer of novel HLA based transplant diagnostics, and Oxford Immunotec, Ltd. (OI), a global diagnostics company part of PerkinElmer Inc., today announce an exclusive sublicense agreement in which PTS will obtain exclusive commercial rights to issued patents protecting a novel assay originally developed by Dr. Oriol Bestard, M.D., Ph.D. - News from Pure Transplant Solutions LLC, issued...

ENewsChannels NEWS: -- Pure Transplant Solutions, LLC (PTS), a developer of novel HLA based transplant diagnostics, and Oxford Immunotec, Ltd. (OI), a global diagnostics company part of PerkinElmer Inc., today announce an exclusive sublicense agreement in which PTS will obtain exclusive commercial rights to issued patents protecting a novel assay originally developed by Dr. Oriol Bestard, M.D., Ph.D. :: News from eNewsChannels

(2) OXFORD, United Kingdom and MARLBOROUGH, Mass., April 29, 2021(NYSE: PKI), today announced that its T-SPOT Discovery SARS-CoV-2 kit will be used for T cell testing in the DIRECT study. Oxford Immunotec is collaborating with researchers at the University of Leicester on DIRECT (Determining the Immune Response in Ethnic minority healthcare workers to COVID-19 infection). The study, funded through the National Core Studies group, is actively recruiting healthcare workers in Leicester for detail...

Oxford Immunotec Global Limite Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell Response and COVID Vaccination in Ethnic Minority Groups Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell Response and COVID Vaccination in Ethnic Minority Groups OXFORD, United Kingdom and MARLBOROUGH, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec a global, high-growth diagnostics company part of P...

Oxford Immunotec’s COVID-19 test to be used in ‘mix and match’ UK vaccine trial 28th April 2021 Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 test kit is set to be used for T cell testing in the UK Com-Cov trial, which is evaluating different combinations of approved COVID-19 vaccines. The Com-Cov study will be the first in the world to evaluate the effects of using different vaccines for the first and second dose within a two-dose vaccination regimen. It will be run by the National Im...

Search jobs 09-Mar-2021 Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE marks T-SPOT ®. COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection   OXFORD, United Kingdom and MARLBOROUG...

The T-SPOT.COVID test was found to agree with PCR test results in over 96 percent of samples taken within first 60 days of infection.

(2) OXFORD, United Kingdom and MARLBOROUGH, Mass., March 4, 2021 /PRNewswire/ -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the "Company"), a global, high-growth diagnostics company, announced that today it has released the T-SPOT. COVID test, a CE marked ELISPOT based test intended for qualitative detection of a cell mediated (T cell) immune response to SARS-CoV-2 in human whole blood. The company has filed an EUA request to the FDA for the test. Serology does not give the full picture of the...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Oxford Immunotec Global PLC New Monthly Series Spotlights What 100 Physicians Find to be Critical Needs in Their Battle Against COVID-19 New Monthly Series Spotlights What 100 Physicians Find to be Critical Needs in Their Battle Against COVID-19 The first survey results reveal physicians seek new diagnostic tools and insights to improve COVID-19 management and patient outcomes OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:...